Filing Flows › Atara Biotherapeutics (ATRA) › Who owns the stock
Who owns Atara Biotherapeutics (ATRA) stock
32 funds reported Atara Biotherapeutics (ATRA) shares in their latest 13F filings, worth $53.6M in all. The largest holder is EcoR1 Capital, LLC ($17.8M). Last quarter 16 funds added to their stakes and 8 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 1,552,000 | $17.8M | increase | 2026-06-30 |
| Adage Capital Partners GP, L.L.C. | 850,000 | $9.8M | increase | 2026-06-30 |
| Point72 Asset Management, L.P. | 687,718 | $7.9M | increase | 2026-06-30 |
| Redmile Group, LLC | 441,701 | $5.1M | unchanged | 2026-06-30 |
| Vanguard Group | 225,940 | $4.1M | increase | 2025-12-31 |
| Vanguard Capital Management LLC | 247,047 | $2.8M | increase | 2026-06-30 |
| Mackenzie Financial | 176,758 | $1.5M | decrease | 2026-09-30 |
| BlackRock | 84,455 | $970K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 75,128 | $863K | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 43,036 | $494K | increase | 2026-06-30 |
| Acadian Asset Management LLC | 38,845 | $444K | decrease | 2026-06-30 |
| Jane Street Group, LLC | 30,345 | $348K | decrease | 2026-06-30 |
| State Street | 26,453 | $304K | unchanged | 2026-06-30 |
| Northern Trust | 16,591 | $190K | increase | 2026-06-30 |
| FMR LLC | 16,238 | $186K | unchanged | 2026-06-30 |
Atara Biotherapeutics' latest quarter
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ATRA stock?
By the latest 13F filings: EcoR1 Capital, LLC ($17.8M); Adage Capital Partners GP, L.L.C. ($9.8M); Point72 Asset Management, L.P. ($7.9M); Redmile Group, LLC ($5.1M); Vanguard Group ($4.1M).
What is the short interest in ATRA?
350,260 shares were sold short at the 2026-10-15 settlement, 8.85% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.